Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 33 | 2023 | 121 | 7.230 |
Why?
|
| Sarcoma | 15 | 2023 | 144 | 2.550 |
Why?
|
| Bone Substitutes | 9 | 2017 | 32 | 2.100 |
Why?
|
| Soft Tissue Neoplasms | 7 | 2022 | 55 | 1.770 |
Why?
|
| Bone Transplantation | 8 | 2017 | 221 | 1.620 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 15 | 1.610 |
Why?
|
| Sarcoma, Ewing | 3 | 2020 | 8 | 1.440 |
Why?
|
| Calcium Sulfate | 6 | 2012 | 27 | 1.080 |
Why?
|
| Musculoskeletal Diseases | 2 | 2015 | 46 | 0.930 |
Why?
|
| Limb Salvage | 5 | 2023 | 12 | 0.910 |
Why?
|
| Humans | 61 | 2023 | 28560 | 0.840 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 206 | 0.820 |
Why?
|
| Retrospective Studies | 27 | 2023 | 3612 | 0.800 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 21 | 0.720 |
Why?
|
| Adult | 24 | 2022 | 8168 | 0.710 |
Why?
|
| Adolescent | 16 | 2021 | 2319 | 0.700 |
Why?
|
| Young Adult | 13 | 2021 | 2102 | 0.700 |
Why?
|
| Osteosarcoma | 8 | 2021 | 37 | 0.700 |
Why?
|
| Calcium Phosphates | 2 | 2012 | 25 | 0.680 |
Why?
|
| Hip Joint | 2 | 2016 | 549 | 0.670 |
Why?
|
| Child | 13 | 2021 | 1423 | 0.670 |
Why?
|
| Fractures, Bone | 2 | 2012 | 75 | 0.650 |
Why?
|
| Bone Cysts | 2 | 2016 | 2 | 0.640 |
Why?
|
| Synovitis, Pigmented Villonodular | 2 | 2016 | 3 | 0.640 |
Why?
|
| Child, Preschool | 9 | 2021 | 690 | 0.630 |
Why?
|
| Tibia | 2 | 2010 | 257 | 0.600 |
Why?
|
| Treatment Outcome | 16 | 2023 | 3620 | 0.560 |
Why?
|
| Male | 26 | 2021 | 15400 | 0.550 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 4 | 0.540 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2022 | 627 | 0.530 |
Why?
|
| Middle Aged | 21 | 2021 | 9316 | 0.530 |
Why?
|
| Bone Diseases | 2 | 2017 | 26 | 0.530 |
Why?
|
| Internal Fixators | 1 | 2016 | 39 | 0.530 |
Why?
|
| Arthrodesis | 2 | 2014 | 42 | 0.520 |
Why?
|
| Foot | 1 | 2016 | 45 | 0.520 |
Why?
|
| Radiotherapy | 1 | 2016 | 34 | 0.510 |
Why?
|
| Foreign Bodies | 1 | 2016 | 30 | 0.510 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 37 | 0.510 |
Why?
|
| Acetabulum | 3 | 2016 | 235 | 0.500 |
Why?
|
| Female | 23 | 2021 | 15818 | 0.500 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 76 | 0.500 |
Why?
|
| Radius | 2 | 2014 | 33 | 0.480 |
Why?
|
| Tobramycin | 2 | 2005 | 10 | 0.450 |
Why?
|
| Knee Prosthesis | 2 | 2008 | 223 | 0.450 |
Why?
|
| Survival Rate | 5 | 2021 | 356 | 0.430 |
Why?
|
| Biopsy | 6 | 2023 | 220 | 0.410 |
Why?
|
| Arthralgia | 2 | 2011 | 125 | 0.410 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 30 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 376 | 0.400 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 33 | 0.390 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 307 | 0.380 |
Why?
|
| Prognosis | 8 | 2023 | 826 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 50 | 0.370 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 4 | 0.370 |
Why?
|
| Talus | 1 | 2011 | 16 | 0.370 |
Why?
|
| Allografts | 4 | 2021 | 222 | 0.360 |
Why?
|
| Edema | 1 | 2011 | 25 | 0.360 |
Why?
|
| Patellar Ligament | 1 | 2010 | 42 | 0.350 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 1863 | 0.350 |
Why?
|
| Humerus | 3 | 2005 | 120 | 0.330 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 553 | 0.330 |
Why?
|
| Prosthesis Failure | 4 | 2022 | 539 | 0.320 |
Why?
|
| Osteomyelitis | 3 | 2005 | 20 | 0.320 |
Why?
|
| Debridement | 3 | 2016 | 102 | 0.310 |
Why?
|
| Femur | 4 | 2022 | 400 | 0.310 |
Why?
|
| Bone Plates | 1 | 2008 | 51 | 0.290 |
Why?
|
| Reoperation | 6 | 2022 | 917 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 66 | 0.280 |
Why?
|
| Cisplatin | 3 | 2017 | 53 | 0.270 |
Why?
|
| Aged | 12 | 2021 | 9334 | 0.270 |
Why?
|
| Osteogenesis | 1 | 2007 | 113 | 0.270 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 822 | 0.250 |
Why?
|
| Curettage | 3 | 2022 | 9 | 0.240 |
Why?
|
| Orthopedic Procedures | 3 | 2004 | 312 | 0.240 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 177 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 63 | 0.240 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4894 | 0.230 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 364 | 0.230 |
Why?
|
| Transplantation, Homologous | 2 | 2004 | 286 | 0.230 |
Why?
|
| Margins of Excision | 2 | 2022 | 31 | 0.230 |
Why?
|
| Infant | 3 | 2021 | 588 | 0.220 |
Why?
|
| Pelvic Bones | 1 | 2004 | 18 | 0.220 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 90 | 0.220 |
Why?
|
| Joint Instability | 1 | 2008 | 400 | 0.220 |
Why?
|
| Knee Joint | 2 | 2008 | 759 | 0.210 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 38 | 0.210 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 60 | 0.210 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 79 | 0.210 |
Why?
|
| Injections | 2 | 2016 | 45 | 0.200 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.200 |
Why?
|
| Prostheses and Implants | 2 | 2015 | 163 | 0.200 |
Why?
|
| Neutrophils | 1 | 2023 | 110 | 0.200 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 371 | 0.200 |
Why?
|
| Absorbable Implants | 1 | 2002 | 27 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 772 | 0.200 |
Why?
|
| Apoptosis | 5 | 2022 | 205 | 0.200 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 11 | 0.200 |
Why?
|
| Vancomycin | 1 | 2002 | 52 | 0.190 |
Why?
|
| Bone Cements | 3 | 2022 | 91 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2021 | 656 | 0.190 |
Why?
|
| Radiography | 5 | 2015 | 651 | 0.190 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 9 | 0.180 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.180 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 9 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 4 | 0.180 |
Why?
|
| Orthopedics | 1 | 2002 | 113 | 0.180 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 19 | 0.170 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 186 | 0.170 |
Why?
|
| Hip Prosthesis | 2 | 2022 | 552 | 0.170 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 249 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 8 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 15 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 190 | 0.160 |
Why?
|
| Dogs | 4 | 2007 | 193 | 0.160 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 61 | 0.150 |
Why?
|
| Medical Oncology | 1 | 2019 | 42 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 81 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 82 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 85 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 110 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 2022 | 332 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 50 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 242 | 0.140 |
Why?
|
| Imidazoles | 1 | 2017 | 55 | 0.140 |
Why?
|
| Piperazines | 1 | 2017 | 80 | 0.130 |
Why?
|
| Ceramics | 1 | 2016 | 22 | 0.130 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 10 | 0.130 |
Why?
|
| Synovectomy | 1 | 2016 | 5 | 0.130 |
Why?
|
| Chondroma | 3 | 2012 | 5 | 0.130 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 95 | 0.130 |
Why?
|
| Child Development | 1 | 2016 | 75 | 0.130 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 4 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2021 | 1940 | 0.120 |
Why?
|
| Time Factors | 3 | 2022 | 1501 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 114 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 31 | 0.120 |
Why?
|
| Supination | 1 | 2014 | 20 | 0.120 |
Why?
|
| Prosthesis Design | 3 | 2022 | 503 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 117 | 0.120 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 36 | 0.120 |
Why?
|
| Arthroplasty | 1 | 2016 | 150 | 0.120 |
Why?
|
| Lung | 1 | 2015 | 170 | 0.120 |
Why?
|
| Hand Strength | 1 | 2014 | 60 | 0.120 |
Why?
|
| Wrist Joint | 1 | 2014 | 62 | 0.110 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 425 | 0.110 |
Why?
|
| Drug Implants | 2 | 2005 | 10 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 13 | 0.110 |
Why?
|
| Risk Factors | 2 | 2022 | 2412 | 0.110 |
Why?
|
| Telomerase | 2 | 2004 | 9 | 0.110 |
Why?
|
| Spinal Fusion | 1 | 2020 | 473 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2013 | 1 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 1194 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 112 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2013 | 22 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2012 | 300 | 0.100 |
Why?
|
| Bone Matrix | 2 | 2003 | 30 | 0.100 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2012 | 3 | 0.100 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 33 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 65 | 0.100 |
Why?
|
| Bone Regeneration | 2 | 2003 | 77 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 373 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 38 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 34 | 0.100 |
Why?
|
| Animals | 5 | 2007 | 3812 | 0.090 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 725 | 0.090 |
Why?
|
| Ankle | 1 | 2011 | 24 | 0.090 |
Why?
|
| Thoracoscopy | 1 | 2010 | 23 | 0.090 |
Why?
|
| Ilium | 1 | 2010 | 29 | 0.090 |
Why?
|
| Age Factors | 2 | 2019 | 788 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 352 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 496 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 939 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2008 | 267 | 0.070 |
Why?
|
| Compressive Strength | 1 | 2007 | 25 | 0.070 |
Why?
|
| Elasticity | 1 | 2007 | 34 | 0.070 |
Why?
|
| Illinois | 1 | 2008 | 247 | 0.070 |
Why?
|
| Cell Division | 3 | 2022 | 83 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1807 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2006 | 32 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 6 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2006 | 47 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 25 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 107 | 0.070 |
Why?
|
| Proteins | 1 | 2006 | 67 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2006 | 106 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 13 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2016 | 149 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 352 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 331 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 89 | 0.060 |
Why?
|
| Blastomycosis | 1 | 2004 | 21 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2023 | 40 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 108 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2023 | 51 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 16 | 0.050 |
Why?
|
| Bone Demineralization Technique | 1 | 2003 | 5 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 16 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 59 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 353 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 63 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 125 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 10 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 12 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 26 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 85 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 10 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2016 | 447 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 31 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 3 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 9 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 20 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 103 | 0.050 |
Why?
|
| Arthroscopy | 1 | 2011 | 1088 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 35 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 47 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 54 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 90 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2004 | 677 | 0.050 |
Why?
|
| SEER Program | 1 | 2021 | 41 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 52 | 0.050 |
Why?
|
| Cartilage | 1 | 2002 | 103 | 0.040 |
Why?
|
| DNA Damage | 2 | 2014 | 28 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 442 | 0.040 |
Why?
|
| Tendons | 1 | 2002 | 225 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 676 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 120 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 120 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 14 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 11 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 53 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 55 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 84 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 10 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 41 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 6 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 179 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 5 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 36 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 45 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 79 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 8 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 17 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 47 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1992 | 135 | 0.020 |
Why?
|
| Acridine Orange | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 5 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 53 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2006 | 17 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 65 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 102 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 120 | 0.020 |
Why?
|
| Manubrium | 1 | 2004 | 2 | 0.010 |
Why?
|
| Sternoclavicular Joint | 1 | 2004 | 6 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2004 | 155 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 120 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 27 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 5 | 0.010 |
Why?
|
| Telomere | 1 | 2002 | 7 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 202 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 59 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 108 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 274 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 309 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 625 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 4 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 6 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 6 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 7 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 15 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 13 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 46 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 24 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 128 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 54 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 51 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 539 | 0.010 |
Why?
|